Vaisala Corporation: Share Repurchase 28.7.2025
STOCK EXCHANGE RELEASE 28.7.2025
Vaisala Corporation: Share Repurchase 28.7.2025
In the Helsinki Stock Exchange
Trade date
28.7.2025
Bourse trade
Buy
Share
VAIAS
Amount
1 500
Shares
Average price/ share
47,0000
EUR
Total cost
70 500,00
EUR
Vaisala Corporation now holds a total of 121 318 shares
including the shares repurchased on 28.7.2025
The share buybacks are executed in compliance with Regulation
No. 596/2014 of the European Parliament and Council (MAR) Article 5
and the Commission Delegated Regulation (EU) 2016/1052.
On behalf of Vaisala Corporation
Nordea Bank Oyj
Sami Huttunen
Ilari Isomäki
More information:Niina Ala-Luopa+358 400 728 957, ir@vaisala.com
Distribution:Nasdaq HelsinkiKey mediavaisala.com
Vaisala is a global leader in measurement instruments and intelligence for climate action. We equip our customers with devices and data to improve resource efficiency, drive energy transition, and care for the safety and well-being of people and societies worldwide. With almost 90 years of innovation and expertise, we employ a team of close to 2,500 experts committed to taking every measure for the planet. Vaisala series A shares are listed on the Nasdaq Helsinki stock exchange. www.vaisala.comAttachment
Vaisala 28.7 trades
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Adyen NV (ADYYF) (H1 2025) Earnings Call Highlights: Strong Growth in Unified Commerce and ...
Net Revenue: EUR 1.1 billion, representing 21% growth on a constant currency basis. EBITDA Growth: 28% increase, with EBITDA margins reaching 50%. Regional Growth: MEIA region grew by 21%, North America by 20%. Digital Segment Growth: 10% increase in net revenues. Unified Commerce Growth: 31% increase in net revenues. Platforms Growth: 55% increase, with 32 platforms processing over a billion euros annually. Warning! GuruFocus has detected 2 Warning Signs with ADYYF. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Adyen NV (ADYYF) reported a resilient first half of 2025 with net revenues growing to approximately EUR1.1 billion, marking a 21% growth on a constant currency basis. The company saw strong growth in its unified commerce segment, with net revenues increasing by 31%, driven by strength in retail, food and beverage, hospitality, and entertainment verticals. Platforms segment was the fastest-growing pillar, with a 55% increase in net revenues, highlighting the success of Adyen's strategy to support platforms in embedding payments. Adyen NV (ADYYF) continues to innovate, with successful product launches like Intel payment routing and Uplift, which have seen high uptake and are helping optimize authorization rates and reduce fraud. The company is expanding its share of wallet with existing customers and adding new customer logos, indicating strong future growth potential. Negative Points Adyen NV (ADYYF) faced negative impacts from macroeconomic factors, including a strong euro and tariffs affecting merchants in the APAC region trading into the US. The growth of Adyen's own customer base was lower than expected, impacting overall growth projections. The company experienced a deceleration in growth from the second half of last year to the first half of this year by about 6 percentage points. Adyen NV (ADYYF) had to adjust its full-year guidance due to the impact of tariffs and macroeconomic challenges, particularly affecting a subset of APAC merchants. Despite strong growth in certain segments, the overall market volume growth was not as high as anticipated, affecting revenue expectations. Q & A Highlights Q: Could you reassure us on the scale of the exposure to the cohort of merchants in Asia selling into the US, and what assumptions have you made for the second half of the year regarding this impact? A: Ethan Tandowsky, CFO, explained that the impact from this subset of customers was significant, with growth approximately 2% lower in Q2 due to this issue. They expect this impact to continue through the second half, which is why they anticipate similar growth rates in H2 as seen in H1. Q: Can you provide more details on the modularized services and how they are resonating with customers? A: Ingo Uytdehaage, Co-CEO, highlighted that modularization is crucial for meeting customer needs. The platform's flexibility allows customers to consolidate services like risk management with Adyen, which can lead to increased acquiring over time. This strategy is aligned with customer stability and growth. Q: How do you see the second half of the year playing out, especially considering the current macroeconomic backdrop? A: Ethan Tandowsky, CFO, stated that they expect second-half net revenue growth to be similar to the first half. The focus remains on expanding share of wallet with existing customers and adding new logos. They are confident in their growth opportunities despite lower market volume growth than initially expected. Q: Can you elaborate on the impact of tariffs and macroeconomic trends on your business? A: Ethan Tandowsky, CFO, noted that the tariff impact was primarily seen in Q2 and is expected to persist through the second half. While macroeconomic trends are mixed with share of wallet gains, the most significant impact was from the APEC merchants, which they have quantified. Q: What are the drivers of growth in LatAm and APAC, and how do you view the potential for stablecoins? A: Ethan Tandowsky, CFO, mentioned strong growth in LatAm due to investments in Brazil and Mexico, while APAC growth is driven by long-term plays in Japan and India. Ingo Uytdehaage, Co-CEO, added that stablecoins could be integrated if customer demand arises, particularly for moving money efficiently in high-inflation scenarios. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Yahoo
Valneva SE (INRLF) (H1 2025) Earnings Call Highlights: Robust Revenue Growth Amid Operational ...
Total Revenue: EUR97.6 million, a 37.8% increase from EUR70.8 million in the first half of 2024. Product Sales: EUR91 million, up 33.3% from EUR68.3 million in the first half of 2024. IXIARO Sales: EUR54.7 million, a 30.6% increase year-over-year. DUKORAL Sales: EUR17.4 million, a 16.4% increase year-over-year. IXCHIQ Sales: EUR7.5 million, up from EUR1 million in the first half of 2024. Gross Margin (excluding IXCHIQ): 59.2%, up from 47.7% in the prior year. IXIARO Gross Margin: 65.5%, compared to 57.5% in the first half of 2024. DUKORAL Gross Margin: 52.9%, compared to 34.8% last year. Operating Loss: EUR16.8 million, compared to an operating profit of EUR46.7 million last year. Adjusted EBITDA: Minus EUR6 million, compared to a positive EUR56.2 million last year. Cash Position: EUR161.3 million as of June 30, 2025. Cash Used in Operations: EUR10.9 million, down from EUR66.3 million in the first half of 2024. 2025 Financial Guidance: Product sales of EUR170 million to EUR180 million; total revenues of EUR180 million to EUR190 million. Warning! GuruFocus has detected 8 Warning Signs with INRLF. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Valneva SE (INRLF) achieved significant year-over-year revenue growth, reaching close to EUR100 million in the first half of 2025. The company maintained a strong cash position of over EUR160 million, indicating effective cash management and reduced operating cash burn. Valneva SE (INRLF) secured additional marketing authorizations for its chikungunya vaccine, IXCHIQ, in the UK, Brazil, and Europe, expanding its market reach. The Lyme disease vaccine candidate, VALOR, is progressing as planned, with Pfizer aiming for regulatory submissions in 2026. The company reported positive Phase III pediatric safety and immunogenicity results for IXCHIQ, reinforcing its potential in the market. Negative Points Valneva SE (INRLF) reported an operating loss of EUR16.8 million in the first half of 2025, compared to an operating profit in the previous year. The company experienced adverse foreign currency fluctuations, impacting revenues by EUR500,000. Research and development expenses increased, driven by costs related to the Shigella vaccine candidate. The company faced temporary restrictions on its chikungunya vaccine, IXCHIQ, due to safety concerns, impacting market uptake. Valneva SE (INRLF) anticipates an acceleration of R&D costs in the second half of 2025, which could further impact financial performance. Q & A Highlights Q: Regarding the 40,000 doses sold to the French government, should we expect any additional revenue recognition in Q3? Also, could you share your perspective on demand scenarios for IXCHIQ through year-end, considering the evolving CHIKV outbreak in the Indian Ocean and China? A: The 40,000 doses were all shipped in the first half of the year, and the revenue was fully recognized in that period. Regarding demand scenarios, we are in contact with governments where outbreaks are occurring. We have no supply constraints and sufficient material available, but it's too early to state where and how we will respond. We aim to stay in control over potential vaccination campaigns given past experiences. Q: For the Lyme vaccine, could you provide insight on how the reporting of data readouts will transpire at year-end? Will the disclosure only report top-line data, or can we expect detailed results? A: The reporting of Phase III results is under Pfizer's responsibility. We expect data readout in two steps: a report on top-line data, primarily efficacy numbers, followed by communication on other endpoints. All data should be out by the end of the first quarter, supporting regulatory submissions around mid-next year. Q: Could you elaborate on what might trigger an acceleration in IXCHIQ sales uptake within the traveler market? Are you still in discussions with the U.S. for potential stockpiling? A: The uncertainty from safety investigations has impacted market uptake. However, the vaccine's profile, especially as a live-attenuated single-shot vaccine, has advantages for outbreak preparedness. We expect new momentum now that restrictions are lifted and investigations concluded. Discussions on stockpiling will hopefully resume later this year. Q: On the Lyme and VALOR trial, suggests a primary completion date of December 26. Are you confident that Phase III headline data will come in 2025, or could it spill into 2026? What is the bar for success in this trial? A: The primary completion date includes safety follow-up periods. Case counts will continue until the end of October, followed by Pfizer's case adjudication and database cleaning. The timing of data readout is not in our control, but Pfizer reaffirms submission timelines. There is no specific communicated bar for approval, but we expect non-inferiority or superiority compared to past vaccines. Q: What should we expect in terms of financial impact from the distribution agreement with CSL? A: The commercial terms with CSL are similar to our previous agreement, so we do not expect an immediate difference in prospects around Germany. However, as CSL gears up, there may be potential upside in the mid- to long term. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Business Upturn
8 hours ago
- Business Upturn
AFARAK GROUP: INTERIM REPORT H1 2025
07:00 London, 09:00 Helsinki, 15 August 2025 – Afarak Group SE ('Afarak' or 'the Company') (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2025 H1/25 H1/ 24 2024 Revenue EUR million 77.1 71.4 128.6 EBITDA EUR million 6.9 4.2 2.6 EBIT EUR million 5.9 3.1 -0.1 Earnings before taxes EUR million 3.4 1.9 -5.3 Profit EUR million 2.4 0.5 -7.2 Earnings per share EUR 0.01 0.00 -0.03 EBITDA margin 9.0% 5.9% 2.0% EBIT margin 7.7% 4.3% -0.1% Earnings margin 4.5% 2.6% -4.1% Personnel (end of period) 613 588 602 FIRST HALF 2025 HIGHLIGHTS Revenue increased by 8% to EUR 77.1 (H1/2024: 71.4) million; Afarak successfully completed the sale of its Ilitha and Zeerust mining assets in South Africa, generating a gain of EUR 2.4 million; Processed material sold increased by 28.8% to 15,354 (H1/2024: 11,922) tonnes; Tonnage mined decreased significantly by 20.5% to 149,410 (H1/2024: 187,958) tonnes; The Group's EBITDA was EUR 6.9 (H1/2024: 4.2) million and the EBITDA margin was 9% (H1/2024: 5.9%); EBIT was EUR 5.9 (H1/2024: 3.1) million, with the EBIT margin at 7.7% (H1/2024: 4.3%); Profit for the period totalled EUR 2.4 (H1/2024: 0.5) million; Cash flow from operations stood at EUR 0.1 (H1/2024: -5.4) million; The interest-bearing debt amounted to EUR 4.9 (30 June 2024: 4.6) (31 December 2024: 2.6) million; Cash and cash equivalents at 30 June totalled EUR 5.8 (30 June 2024: 10.1) (31 December 2024: 3.9) million. OUTLOOK FOR THE SECOND HALF OF 2025 The market for standard grade low carbon ferro-chrome is expected to be stable throughout the year with some modest upwards potential. The weak US$ could easily wipe out any price increases, and cheap imports especially from Kazakhstan, and in a lesser way from Turkey and India/China will continue to weigh on the market price development. The specialty segment may be seeing more substantial improvements in demand and prices. The chrome ore business, on the other hand, is expected to produce better margins. We have been finalizing investment decisions that will enable us to swiftly increase the output of chrome ore concentrates in South Africa. A new wash plant is planned to be commissioned by end of September in our Vlaakport mine, together with a solar energy plant which will make us independent from the grid there and allow us to produce on steady and regular basis concentrates with high quality ratios. The Mecklenburg mine is also expected to increase output substantially. By selling Ilitha and Zeerust, our South African team is now able to focus fully on these two assets. CEO Mr. Guy Konsbruck Afarak managed to present substantially improved EBITDA and profit margins compared to H1/2024 in an extremely competitive and complicated market. The tariff escalation between USA and Europe, the geopolitical uncertainties did not support a positive evolution of the business environment. Internally, unexpected boulder zones caused set-backs in the mining operations in Mecklenburg, which entailed a low production of Chrome ore. Hence, we could not achieve the expected results in that segment. The fact that 80% of our sales happen in the USD currency which has strongly devaluated, added another adverse condition to this picture. Under the light of all the above, we can be satisfied with the results of H1/2025. Afarak has been for many years now the only Western producer of low carbon ferro-chrome, a critical material for production for Aerospace, Defense, Automotive, Green energies, and various other industries. Helsinki, August 15, 2025 Afarak Group SE Board of Directors For additional information, please contact: Guy Konsbruck, CEO, +356 2122 1566, [email protected] Financial reports and other investor information are available on the Company's website: Afarak Group is a specialist alloy producer focused on delivering sustainable growth with a Speciality Alloys business in southern Europe and a FerroAlloys business in South Africa. The Company is listed on NASDAQ Helsinki (AFAGR) and the Main Market of the London Stock Exchange (AFRK). Distribution:NASDAQ HelsinkiLondon Stock ExchangeMain media
